Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis

Hurley, Margaret M.; Forrester, Douglas L; Smyth, Alan

doi:10.1002/14651858.cd008037.pub2

Cited by 9 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of infectious disease, adjuvants have been defined as ‘therapies that act by rendering the organism more susceptible to attack by antibiotics or the host immune system, by rendering the organism less virulent or killing it by other means’. 172 A number of approaches have been proposed as candidates for adjuvant therapy in NTM infection in CF, including interferon γ (IFNγ; or agents that promote IFNγ release) and vitamin D. Drug delivery vehicles, such as liposomes, may be considered adjuvants. Liposomes have been studied as a mode of delivering amikacin for infection with P. aeruginosa in CF, 173 and this approach is also being evaluated (clinicaltrials.gov/show/NCT01315236) for NTM.…”

Section: Treatmentmentioning

confidence: 99%

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

Floto

Olivier

Saiman

et al. 2015

Thorax

Self Cite

404

456

View full text Add to dashboard Cite

Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease such as cystic fibrosis (CF). Pulmonary disease caused by NTM has emerged as a major threat to the health of individuals with CF but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened an expert panel of specialists to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM pulmonary disease in individuals with CF. Nineteen experts were invited to participate in the recommendation development process. Population, Intervention, Comparison, Outcome (PICO) methodology and systematic literature reviews were employed to inform draft recommendations. An anonymous voting process was used by the committee to reach consensus. All committee members were asked to rate each statement on a scale of: 0, completely disagree, to 9, completely agree; with 80% or more of scores between 7 and 9 being considered ‘good’ agreement. Additionally, the committee solicited feedback from the CF communities in the USA and Europe and considered the feedback in the development of the final recommendation statements. Three rounds of voting were conducted to achieve 80% consensus for each recommendation statement. Through this process, we have generated a series of pragmatic, evidence-based recommendations for the screening, investigation, diagnosis and treatment of NTM infection in individuals with CF as an initial step in optimising management for this challenging condition.

show abstract

Section: Treatmentmentioning

confidence: 99%

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

Floto

Olivier

Saiman

et al. 2015

Thorax

Self Cite

404

456

View full text Add to dashboard Cite

show abstract

“…CA-MRSA is reported as the most common cause of purulent skin and soft tissue infections in the US [39]. It is assessed that S. aureus accounts for 12 million outpatient visits and 292,000 hospitalizations of which 126,000 are due to MRSA annually in the US alone [38].…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, probiotic treatments, which are relatively independent on patients’ health matters, have little or no interference with commensal microbes may complement antibiotics or PEG-DMA on the growth of various skin microbes have been not examined in this study, we believe that PEG-DMA will not systemically induce an imbalance of the human microbiome since it is applied locally onto a skin wound. Besides the function of PEG-DMA as a SFI, we believe that when PEG-DMA is used with antibiotics, it has potential to be an antibiotic adjuvant [39] to augment the fermentation activity of S. epidermidis and reduce the effective doses of antibiotics, decreasing the risk of generating resistant S. aureus and non-specific killing effect of antibiotics on skin commensals. Many bacteria can selectively use substrates from a mixture of different carbon sources via the regulation of carbon catabolite repression (CCR) [40].…”

Section: Discussionmentioning

confidence: 99%

Microbiome precision editing: Using PEG as a selective fermentation initiator against methicillin‐resistant Staphylococcus aureus

Kao

Huang

Chang

et al. 2017

Biotechnology Journal

View full text Add to dashboard Cite

Recent creation of a Unified Microbiome Initiative (UMI) has the aim of understanding how microbes interact with each other and with us. When pathogenic Staphylococcus aureus (S. aureus) infects the skin, the interplay between S. aureus and skin commensal bacteria occurs. Our previous data revealed that skin commensal bacteria can mediate fermentation against the growth of USA300, a community-acquired methicillin-resistant S. aureus MRSA (CA-MRSA). By using a fermentation process with solid media on a small scale, we define poly(ethylene glycol) dimethacrylate (PEG-DMA) as a selective fermentation initiator (SFI) which can specifically intensify the probiotic ability of skin commensal Staphylococcus epidermidis (S. epidermidis) bacteria. At least five SCFAs including acetic, butyric and propionic acids with anti-USA300 activities were produced by PEG-DMA fermentation of S. epidermidis. Furthermore, the S. epidermidis-laden PEG-DMA hydrogels effectively decolonized USA300 in skin wounds in mice. The PEG-DMA and its derivatives may become novel biomaterials to specifically tailor the human skin microbiome against invading pathogens.

show abstract

“…The emergence of increasingly resistant bacteria and the infections sustained by biofilm make the treatment of CF airway infection a great medical challenge [135]. Therefore, there is a pressing need to develop new therapeutic approaches to cure CF airway infections.…”

Section: Future Approaches In the Therapy Of Cf Airway Infectionsmentioning

confidence: 99%